FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308134181> ?p ?o ?g. }

• W4308134181 endingPage "A61" @default.
• W4308134181 startingPage "A60" @default.
• W4308134181 abstract "Abstract Here we present the design and early findings from CAH-300 /NCT05101902, a prescreening protocol to identify participants who are potentially eligible for the CAH-301 Phase 1/2 treatment trial with BBP-631, an AAV5-based gene therapy for classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD). The CYP21A2 gene encodes the 21-hydroxylase enzyme that plays a critical role in glucocorticoid and mineralocorticoid synthesis by the adrenal cortex. CYP21A2pathogenic variants cause 21OHD, the most common form of CAH, characterized by variable degrees of adrenal insufficiency and androgen excess. Standard treatment of classic CAH due to 21OHD usually consists of daily replacement doses of glucocorticoid (GC) and mineralocorticoid. However, supraphysiologic GC doses are often required to mitigate the androgen excess and it is difficult to dose exogenous GCs in a manner that provides adequate disease control while avoiding overtreatment. A gene therapy approach offers the potential to restore cortisol and aldosterone production from the adrenal glands in a physiologically regulated manner. To assess potential eligibility for the gene therapy trial CAH-301, participants in the prescreening protocol CAH-300 undergo initial assessments for the presence of exclusionary anti-21OH antibodies and anti-AAV5 antibodies, as well as for characterization of CYP21A2 genotype. After the participant meets initial eligibility criteria, referral to a treatment trial center may be arranged. To address the challenges in recruiting participants with this rare disorder, prescreening assessments are performed at the participant's home allowing for recruitment from broad geographic areas including those without proximity to a tertiary care center. Home assessments have also provided flexibility for participants during the COVID pandemic. Additional assessments during prescreening that further impact eligibility for the gene therapy trial include review of participant medical history and collection of hormonal biomarkers including 17-hydroxyprogestone, androstenedione, cortisol, and ACTH. Preliminary laboratory data show the expected presence of low cortisol (measured by both gas chromatography-mass spectrometry and immunoassay) with concomitant elevated ACTH, confirming the potential to detect meaningful changes in endogenous cortisol production after BBP-631 dosing. In summary, our prescreening approach with home assessments has enabled the efficient identification of participants potentially eligible for the CAH-301 gene therapy trial. Preliminary data have confirmed the presence of low cortisol and thus potential for detecting meaningful increases in endogenous cortisol production after gene therapy with BBP-631. Presentation: No date and time listed" @default.
• W4308134181 created "2022-11-08" @default.
• W4308134181 creator A5015999610 @default.
• W4308134181 creator A5020296118 @default.
• W4308134181 creator A5025724513 @default.
• W4308134181 creator A5046724653 @default.
• W4308134181 creator A5047678352 @default.
• W4308134181 creator A5055037280 @default.
• W4308134181 creator A5055821983 @default.
• W4308134181 creator A5066465731 @default.
• W4308134181 creator A5079272472 @default.
• W4308134181 date "2022-11-01" @default.
• W4308134181 modified "2023-10-14" @default.
• W4308134181 title "ODP046 Initial Lessons from a Prescreening Protocol to Identify Participants with Classic CAH Potentially Eligible for Gene Therapy Treatment with BBP-631, an Adeno-associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene" @default.
• W4308134181 doi "https://doi.org/10.1210/jendso/bvac150.125" @default.
• W4308134181 hasPublicationYear "2022" @default.
• W4308134181 type Work @default.
• W4308134181 citedByCount "1" @default.
• W4308134181 countsByYear W43081341812023 @default.
• W4308134181 crossrefType "journal-article" @default.
• W4308134181 hasAuthorship W4308134181A5015999610 @default.
• W4308134181 hasAuthorship W4308134181A5020296118 @default.
• W4308134181 hasAuthorship W4308134181A5025724513 @default.
• W4308134181 hasAuthorship W4308134181A5046724653 @default.
• W4308134181 hasAuthorship W4308134181A5047678352 @default.
• W4308134181 hasAuthorship W4308134181A5055037280 @default.
• W4308134181 hasAuthorship W4308134181A5055821983 @default.
• W4308134181 hasAuthorship W4308134181A5066465731 @default.
• W4308134181 hasAuthorship W4308134181A5079272472 @default.
• W4308134181 hasBestOaLocation W43081341811 @default.
• W4308134181 hasConcept C104317684 @default.
• W4308134181 hasConcept C111599444 @default.
• W4308134181 hasConcept C126322002 @default.
• W4308134181 hasConcept C134018914 @default.
• W4308134181 hasConcept C187212893 @default.
• W4308134181 hasConcept C2776069600 @default.
• W4308134181 hasConcept C2777767042 @default.
• W4308134181 hasConcept C2780841215 @default.
• W4308134181 hasConcept C54355233 @default.
• W4308134181 hasConcept C71924100 @default.
• W4308134181 hasConcept C86803240 @default.
• W4308134181 hasConceptScore W4308134181C104317684 @default.
• W4308134181 hasConceptScore W4308134181C111599444 @default.
• W4308134181 hasConceptScore W4308134181C126322002 @default.
• W4308134181 hasConceptScore W4308134181C134018914 @default.
• W4308134181 hasConceptScore W4308134181C187212893 @default.
• W4308134181 hasConceptScore W4308134181C2776069600 @default.
• W4308134181 hasConceptScore W4308134181C2777767042 @default.
• W4308134181 hasConceptScore W4308134181C2780841215 @default.
• W4308134181 hasConceptScore W4308134181C54355233 @default.
• W4308134181 hasConceptScore W4308134181C71924100 @default.
• W4308134181 hasConceptScore W4308134181C86803240 @default.
• W4308134181 hasIssue "Supplement_1" @default.
• W4308134181 hasLocation W43081341811 @default.
• W4308134181 hasLocation W43081341812 @default.
• W4308134181 hasOpenAccess W4308134181 @default.
• W4308134181 hasPrimaryLocation W43081341811 @default.
• W4308134181 hasRelatedWork W1989365606 @default.
• W4308134181 hasRelatedWork W1998785790 @default.
• W4308134181 hasRelatedWork W2084912383 @default.
• W4308134181 hasRelatedWork W2092107317 @default.
• W4308134181 hasRelatedWork W2101834938 @default.
• W4308134181 hasRelatedWork W2104949955 @default.
• W4308134181 hasRelatedWork W2156866593 @default.
• W4308134181 hasRelatedWork W2276893008 @default.
• W4308134181 hasRelatedWork W2311309180 @default.
• W4308134181 hasRelatedWork W4232773839 @default.
• W4308134181 hasVolume "6" @default.
• W4308134181 isParatext "false" @default.
• W4308134181 isRetracted "false" @default.
• W4308134181 workType "article" @default.